Study Details
A study to find out if fezolinetant helps reduce moderate to severe hot flashes in women in Asia going through menopause
Clinicaltrials.gov ID
Astellas Study ID
2693-CL-0305
EudraCT ID
N/A
Condition
Hot Flashes
Phase
Phase 3
Age
40 Years - 65 Years
Sex
Female
Product
fezolinetant
Type
Interventional
Trial Dates
Mar 2020 - Apr 2022
Masking
Double (Participant, Investigator)
Enrollment number
302
A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women in Asia Suffering from Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study to find out if fezolinetant helps reduce moderate to severe hot flashes in women in Asia going through menopause? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site CN86037
Chengdu, China
Site CN86011
Nanjing, China
Site CN86026
Nanning, China
Site TW88609
Tainan, Taiwan, Province of China
Site CN86022
Changchun, China
Site CN86034
Hangzhou, China
Site CN86023
Taiyuan, China
Site CN86015
Tianjin, China
Site CN86001
Beijing, China
Site TW88605
Kaohsiung City, Taiwan, Province of China
Site CN86002
Beijing, China
Site TW88611
Taipei, Taiwan, Province of China
Site KR82004
Seoul, Republic of Korea
Site KR82012
Seoul, Republic of Korea
Site KR82003
Seongnam-si, Republic of Korea
Site TW88608
Kaohsiung City, Taiwan, Province of China
Site CN86025
Hangzhou, China
Site CN86041
Yangzhou, China
Site CN86013
Yinchuan, China
Site KR82001
Seoul, Republic of Korea
Site CN86029
Tianjin, China
Site CN86043
Guangzhou, China
Site KR82007
Seoul, Republic of Korea
Site CN86007
Shijiazhuang, China
Site CN86006
Guangzhou, China
Site CN86038
Suzhou, China
Site TW88601
Taipei, Taiwan, Province of China
Site KR82006
Seoul, Republic of Korea
Site CN86019
Guangzhou, China
Site KR82009
Busan, Republic of Korea
Site CN86008
Wuhan, China
Site KR82002
Seoul, Republic of Korea
Site KR82013
Ansan-si, Republic of Korea
Site CN86005
Liuzhou, China
Site CN86028
Yangzhou, China
Site CN86033
Zhongshan, China
Site KR82011
Seongnam-si, Republic of Korea
Site TW88604
New Taipei City, Taiwan, Province of China
Site CN86004
Nanjing, China
Site KR82005
Busan, Republic of Korea
Site TW88607
Taipei, Taiwan, Province of China
Site CN86020
Lanzhou, China
Site CN86021
Shenzhen, China
Site TW88606
Taichung, Taiwan, Province of China
Site TW88603
Tainan, Taiwan, Province of China
Site CN86009
Changsha, China
Site TW88602
Tainan, Taiwan, Province of China
Site CN86012
Shanghai, China
Site CN86039
Fuzhou, China
Site CN86027
Kunming, China
Site CN86030
Beijing, China
Site CN86042
Guangzhou, China
Site CN86031
Taiyuan, China
Site CN86018
Guiyang, China
Site CN86032
Nanning, China
Site CN86035
Nanjing, China
Site CN86040
Dalian, China
Site CN86017
Beijing, China
Site CN86016
Tianjin, China
Site TW88610
Putzu, Taiwan, Province of China